NCT03965871.
Methods | Randomised, multiple dose, placebo‐controlled, double‐blind, multicentre study |
Participants | 88 participants with bipolar depression |
Interventions | Drug: esketamine DPI ‐ low dose Drug: esketamine DPI ‐ medium dose Drug: esketamine DPI ‐ high dose Drug: placebo DPI |
Outcomes | MADRS Response Remission Time to relapse C‐SSRS BPRS YMRS Adverse events |
Notes | Trial completed February 2021, no results available yet. |